Omentin-1 vs L-692,429
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and L-692,429 (L-692,429) — benefits, dosing, side effects, research data, and where to buy.
| Property | Omentin-1 | L-692,429 |
|---|---|---|
| Category | Diabetes & Metabolic | Growth Hormone |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | L-692,429 |
| Molecular Weight | ~35 kDa | N/A |
| Half-Life | hours | unknown / study-dependent |
| Amino Acids | 313 | N/A |
| Typical Dose | No approved human dose; research use only | 0.03-0.1 mg/kg |
| Route | IV|SC | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 30 |
| Research Status | Pre-clinical | Pre-clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
L-692,429 Benefits
- ✓potent GHSR agonism
- ✓oral bioactivity in models
- ✓validates ghrelin pathway
- ✓useful research probe
Omentin-1 Dosing
not established|not established
L-692,429 Dosing
0.03-0.1 mg/kg in early studies|single oral or short-course research dosing|serial GH sampling recommended
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
L-692,429 Side Effects
- ⚠increased appetite
- ⚠glucose intolerance
- ⚠transient prolactin changes
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
L-692,429
L-692,429 was important in early GH secretagogue research because it showed that nonpeptide molecules could trigger robust GH release. It remains a classic tool compound for studying receptor-mediated GH pulsatility and appetite signaling.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.